Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P S Sorensen

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
European Journal of Neurology|April 15, 2009
How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?P S Sorensen
European Journal of Neurology|December 18, 2008
Management of patients with neutralizing antibodies against interferon-beta: stop IFN-beta therapy or wait for the antibodies to go away?P S Sorensen
Archives of Neurology|August 17, 1999
Intravenous immunoglobulin treatment in neurologic disorders: yesP S Sorensen
Ugeskrift for Laeger|May 19, 1975
[Giant cell arteritis. Temporal arteritis and polymyalgia rheumatica]P S Sorensen, I Lorenzen
European Journal of Neurology|November 28, 2002
Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysisP S Sorensen, F Fazekas, M Lee
Journal of Neuroimmunology|November 4, 2006
CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosisM Krakauer, P S Sorensen, F Sellebjerg
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 6, 2007
Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?P S Sorensen, N Koch-Henriksen, K Bendtzen
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 29, 2008
Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?P S Sorensen, N Koch-Henriksen, E M Flachs, et al.
Scandinavian Journal of Immunology|July 27, 2006
Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosisM Krakauer, P S Sorensen, M Khademi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2009
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosisN Koch-Henriksen, P S Sorensen, K Bendtzen, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
European Journal of Neurology|April 15, 2009
How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?P S Sorensen
European Journal of Neurology|December 18, 2008
Management of patients with neutralizing antibodies against interferon-beta: stop IFN-beta therapy or wait for the antibodies to go away?P S Sorensen
Archives of Neurology|August 17, 1999
Intravenous immunoglobulin treatment in neurologic disorders: yesP S Sorensen
Ugeskrift for Laeger|May 19, 1975
[Giant cell arteritis. Temporal arteritis and polymyalgia rheumatica]P S Sorensen, I Lorenzen
European Journal of Neurology|November 28, 2002
Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysisP S Sorensen, F Fazekas, M Lee
Journal of Neuroimmunology|November 4, 2006
CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosisM Krakauer, P S Sorensen, F Sellebjerg
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 6, 2007
Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?P S Sorensen, N Koch-Henriksen, K Bendtzen
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 29, 2008
Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?P S Sorensen, N Koch-Henriksen, E M Flachs, et al.
Scandinavian Journal of Immunology|July 27, 2006
Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosisM Krakauer, P S Sorensen, M Khademi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2009
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosisN Koch-Henriksen, P S Sorensen, K Bendtzen, et al.
Pageof 4